Company / R&D Expense
Aurinia Pharmaceuticals Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$32.5M
FY2025
5-year range
$20.8M / $52.9M
FY2021-FY2025
Trend
+56.4%
vs FY2024
Sector context
#190 of 210
Health Care
What the data says
Among 210 Health Care companies, Aurinia Pharmaceuticals Inc. is in the bottom 10% for r&d expense. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $33M.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of -8.4%.
Declined from $50M to $33M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -13.6%
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 210This company $32.5M Sector average $644.0M
▼
-95.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, r&d expense increased 56.4% year-over-year.
- Ranks #190 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.5M | +56.4% |
| FY2024 | $20.8M | -58.1% |
| FY2023 | $49.6M | -1.4% |
| FY2022 | $50.3M | -4.8% |
| FY2021 | $52.9M | +5.0% |
| FY2020 | $50.3M | -4.8% |
| FY2019 | $52.9M | +27.8% |
| FY2018 | $41.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026